Profile data is unavailable for this security.
About the company
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
- Revenue in SEK (TTM)3.55bn
- Net income in SEK-3.81bn
- Incorporated1989
- Employees1.10k
- LocationVitrolife ABGustaf Werners gata 2, Vastra FrolundaGOETEBORG 421 32SwedenSWE
- Phone+46 317218000
- Fax+46 317218099
- Websitehttps://www.vitrolife.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arjo AB (publ) | 11.18bn | 511.00m | 9.02bn | 6.85k | 18.92 | 1.23 | 6.03 | 0.8069 | 1.88 | 1.88 | 41.05 | 28.87 | 0.7149 | 4.54 | 6.78 | 1,644,896.00 | 3.26 | 3.55 | 4.62 | 5.55 | 43.64 | 44.01 | 4.56 | 5.41 | 0.626 | 3.97 | 0.4073 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
| Revenio Group Oyj | 1.18bn | 220.42m | 9.05bn | 230.00 | 40.62 | 7.69 | 32.19 | 7.65 | 0.7204 | 0.7204 | 3.86 | 3.81 | 0.7834 | 4.93 | 8.17 | 472,574.10 | 14.67 | 14.33 | 17.09 | 17.90 | 49.29 | 50.73 | 18.72 | 21.13 | 1.51 | 34.57 | 0.1276 | 55.81 | -0.4125 | 25.80 | -12.15 | 18.72 | 17.67 | 6.30 |
| Biotage AB | 2.13bn | 257.00m | 13.03bn | 675.00 | 50.72 | 3.42 | 29.75 | 6.13 | 3.21 | 3.21 | 26.56 | 47.60 | 0.4312 | 1.59 | 7.22 | 3,155,786.00 | 5.21 | 10.74 | 6.05 | 12.77 | 62.67 | 61.40 | 12.08 | 15.75 | 1.15 | 43.88 | 0.0616 | 40.11 | 19.54 | 15.50 | -8.21 | 7.97 | 14.05 | 1.30 |
| ChemoMetec A/S | 634.26m | 211.93m | 13.11bn | 173.00 | 61.85 | 14.91 | 54.74 | 20.67 | 7.83 | 7.83 | 23.44 | 32.48 | 0.6112 | 0.745 | 6.97 | 2,357,630.00 | 20.42 | 27.96 | 24.40 | 35.10 | 78.80 | 79.57 | 33.41 | 35.02 | 3.76 | -- | 0.0073 | 144.08 | -8.22 | 18.37 | -23.72 | 26.64 | 9.97 | -11.81 |
| Xvivo Perfusion AB | 750.59m | 204.27m | 14.19bn | 161.00 | 68.47 | 6.81 | 51.42 | 18.91 | 6.58 | 6.58 | 24.07 | 66.13 | 0.3325 | 1.14 | 4.67 | 4,691,194.00 | 9.05 | 1.24 | 9.68 | 1.33 | 74.41 | 73.14 | 27.21 | 4.76 | 4.23 | -- | 0.0117 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
| AddLife AB | 10.01bn | 117.00m | 16.34bn | 2.36k | 144.47 | 3.30 | 15.58 | 1.63 | 0.9601 | 0.9601 | 82.16 | 42.09 | 0.7625 | 3.50 | 5.58 | 4,351,152.00 | 0.9063 | 5.31 | 1.29 | 8.83 | 37.30 | 36.89 | 1.19 | 5.79 | 0.638 | 1.66 | 0.5146 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| Embla Medical hf | 9.09bn | 747.11m | 23.86bn | 4.00k | 32.14 | 2.81 | 17.85 | 2.62 | 1.12 | 1.12 | 13.55 | 12.76 | 0.5755 | 2.23 | 6.65 | 1,461,696.00 | 4.75 | 4.06 | 5.51 | 4.76 | 62.02 | 62.47 | 8.25 | 6.91 | 1.26 | 6.59 | 0.4074 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
| Elekta AB (publ) | 18.12bn | 1.13bn | 24.00bn | 4.57k | 21.97 | 2.32 | 10.39 | 1.32 | 2.96 | 2.96 | 47.38 | 28.01 | 0.5822 | 3.16 | 2.89 | 3,903,469.00 | 3.65 | 4.19 | 6.53 | 7.51 | 36.76 | 39.03 | 6.27 | 7.37 | 0.7425 | 3.91 | 0.4196 | 68.60 | 7.41 | 5.98 | 38.07 | 1.68 | 20.06 | 5.92 |
| Vitrolife AB | 3.55bn | -3.81bn | 32.51bn | 1.10k | -- | 2.47 | -- | 9.15 | -28.10 | -28.10 | 26.24 | 97.03 | 0.1867 | 3.48 | 6.48 | 3,293,791.00 | -19.99 | -4.57 | -20.71 | -4.78 | 58.16 | 58.38 | -107.03 | -21.89 | 2.36 | 9.24 | 0.135 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
| Ambu A/S | 8.38bn | 365.44m | 45.25bn | 5.20k | 140.11 | 5.90 | 31.26 | 5.40 | 0.8839 | 0.8839 | 20.26 | 21.00 | 0.7694 | 2.21 | 7.14 | 1,037,529.00 | 3.35 | 3.22 | 3.91 | 3.87 | 59.38 | 59.54 | 4.36 | 4.43 | 1.47 | 58.64 | 0.0907 | 25.41 | 12.90 | 13.84 | 39.88 | -5.81 | 2.06 | 0.00 |
| Getinge AB | 33.59bn | 1.69bn | 49.38bn | 11.85k | 31.30 | 1.75 | 13.43 | 1.47 | 6.21 | 6.21 | 123.33 | 111.09 | 0.5937 | 2.51 | 7.30 | 2,861,487.00 | 3.01 | 5.31 | 4.00 | 6.98 | 45.80 | 47.83 | 5.07 | 8.69 | 0.5965 | 10.34 | 0.2629 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
| Sectra AB | 1.81bn | 447.23m | 52.06bn | 1.22k | 124.38 | 33.62 | 95.19 | 28.76 | 2.31 | 2.31 | 9.36 | 8.55 | 0.6136 | -- | 3.63 | 1,503,436.00 | 15.16 | 15.75 | 28.08 | 29.52 | 47.01 | 64.95 | 24.71 | 19.59 | -- | -- | 0.027 | 0.00 | 26.84 | 4.06 | 14.25 | 16.58 | 48.37 | -- |
| Demant A/S | 34.79bn | 4.12bn | 90.15bn | 21.50k | 21.88 | 6.05 | -- | 2.59 | 11.98 | 10.92 | 101.23 | 43.36 | 0.7192 | 2.03 | 5.68 | 1,034,778.00 | 8.52 | 8.27 | 11.68 | 13.23 | 75.45 | 74.14 | 11.85 | 11.34 | 1.06 | 5.58 | 0.6244 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
Data as of Nov 11 2024. Currency figures normalised to Vitrolife AB's reporting currency: Swedish Krona SEK
23.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AMF Fonder ABas of 04 Jan 2024 | 6.90m | 5.09% |
| Fj�rde AP-fondenas of 30 Jun 2024 | 4.81m | 3.55% |
| Swedbank Robur Fonder ABas of 30 Sep 2024 | 4.55m | 3.36% |
| Handelsbanken Fonder ABas of 31 Oct 2024 | 3.06m | 2.26% |
| SEB Investment Management ABas of 30 Sep 2024 | 2.77m | 2.04% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 2.36m | 1.74% |
| Cliens Kapitalf�rvaltning ABas of 31 Dec 2023 | 2.28m | 1.68% |
| Tredje AP-fondenas of 31 Aug 2023 | 1.74m | 1.29% |
| Norges Bank Investment Managementas of 31 Aug 2023 | 1.53m | 1.13% |
| L�nsf�rs�kringar Fondf�rvaltning ABas of 30 Sep 2024 | 1.48m | 1.10% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
